Antoin Douglawi

Urology
26780 Barton Rd
Redlands, CA 92373

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes.

Optimizing testicular cancer therapy: Survivorship perspectives on reducing late toxicities without compromising outcomes.

Journal: Urologic oncology
Published: January 25, 2026

Mental Health Burden of a Testicular Cancer Diagnosis: Insights From a Large Claims Database.

Mental Health Burden of a Testicular Cancer Diagnosis: Insights From a Large Claims Database.

Journal: Urology
Published: December 04, 2025

Persistent suicide risk in survivors of testicular cancer: A population-based cohort study.

Persistent suicide risk in survivors of testicular cancer: A population-based cohort study.

Journal: Urologic oncology
Published: November 26, 2025

Outcomes of Prophylactic Ureteral Catheterization for Ureteral Identification During Non-Urologic Surgery.

Outcomes of Prophylactic Ureteral Catheterization for Ureteral Identification During Non-Urologic Surgery.

Journal: Journal of endourology
Published: October 31, 2025

Invasive Primary Melanoma of the Kidney: A Rare Presentation of an Uncommon Malignancy and Review of Literature.

Invasive Primary Melanoma of the Kidney: A Rare Presentation of an Uncommon Malignancy and Review of Literature.

Journal: Case reports in urology
Published: October 26, 2025

The association between perioperative activity levels and discharge outcomes after radical cystectomy.

The association between perioperative activity levels and discharge outcomes after radical cystectomy.

Journal: Urologic oncology
Published: December 19, 2024

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology
Published: October 28, 2024

Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors.

Eleven-Year Experience With Midline Extraperitoneal Retroperitoneal Lymph Node Dissection for Germ Cell Tumors.

Journal: The Journal of urology
Published: September 13, 2024

Opioid prescription following radical orchiectomy associated with new persistent opioid use.

Opioid prescription following radical orchiectomy associated with new persistent opioid use.

Journal: Urologic oncology
Published: February 18, 2024

Corrigendum re "A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)" [Eur Urol Focus 2022;8:173-81].

Corrigendum re "A Preoperative Nomogram to Predict Renal Function Insufficiency for Cisplatin-based Adjuvant Chemotherapy Following Minimally Invasive Radical Nephroureterectomy (ROBUUST Collaborative Group)" [Eur Urol Focus 2022;8:173-81].

Journal: European urology focus
Published: January 01, 2023

Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.

Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospective cohort study.

Journal: European journal of cancer (Oxford, England : 1990)
Published: December 03, 2022

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re: Isamu Tachibana, Sean Q. Kern, Antoin Douglawi, et al. Primary Retroperitoneal Lymph Node Dissection for Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumor-N1, N2, and N3 Disease: Is Adjuvant Chemotherapy Necessary? J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00118: Is Retroperitoneal Lymph Node Dissection Without Adjuvant Chemotherapy Enough for All Patients with Pathologic Stage II Nonseminoma Germ Cell Tumor?

Journal: European urology
Published: September 06, 2022
Showing 1-12 of 27

Last Updated: 09/26/2026